Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Svas Biosana SpAMIL:SVS 78 3-Year EBITDA Growth Rate is 18.70% as of Dec. 2025, which is at its 10-year median of 18.70. GuruFocus rates MIL:SVS with a GF Score™ of 78/100 and a GF Value™ of €9.63 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 689 Medical Devices & Instruments companies, Svas Biosana SpA ranks better than 64.3% on this metric.
During the past 12 months, Svas Biosana SpA's average EBITDA Per Share Growth Rate was 5.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 18.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 17.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Svas Biosana SpA was 21.10% per year. The lowest was 7.80% per year. And the median was 18.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Svas Biosana SpA 3-Year EBITDA Growth Rate Related Terms
MIL:SVS vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Svas Biosana SpA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Svas Biosana SpA 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Svas Biosana SpA's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Svas Biosana SpA's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 18.70% mean?
Svas Biosana SpA (MIL:SVS) has a 3-Year EBITDA Growth Rate of 18.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Svas Biosana SpA and its competitors. This is near median its historical median of 18.70. Over the past decade, Svas Biosana SpA's 3-Year EBITDA Growth Rate has ranged from 7.80 to 21.10. According to the industry distribution chart, Svas Biosana SpA ranks #246 out of 689 companies in the Medical Devices & Instruments industry, placing it in the top 35.7%.
Is Svas Biosana SpA's 3-Year EBITDA Growth Rate too high?
Svas Biosana SpA's current 3-Year EBITDA Growth Rate of 18.70% is near median its 10-year median of 18.70. Over the past 10 years, this metric has ranged from a low of 7.80 to a high of 21.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.70. Svas Biosana SpA's value of 18.70% is 142.9% above this industry median. Based on the distribution chart, Svas Biosana SpA ranks #246 out of 689 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Svas Biosana SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Svas Biosana SpA's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Svas Biosana SpA ranks #246 out of 689 companies for 3-Year EBITDA Growth Rate. This puts Svas Biosana SpA in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.70. Svas Biosana SpA's value of 18.70% is 142.9% above this benchmark. Historically, Svas Biosana SpA's own 3-Year EBITDA Growth Rate has ranged from 7.80 to 21.10 over the past decade. While the company's 10-year median is 18.70 vs. the industry median of 7.70, Svas Biosana SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Svas Biosana SpA's current 3-Year EBITDA Growth Rate of 18.70% is 142.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Svas Biosana SpA and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Svas Biosana SpA's current 3-Year EBITDA Growth Rate is 18.70%, which is near median its own 10-year median of 18.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Svas Biosana SpA stock overvalued right now?
Based on GuruFocus' analysis, Svas Biosana SpA (MIL:SVS) is currently considered Modestly Undervalued. The stock's GF Value™ is €9.63, compared to a current price of €8.00 — trading 16.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 18.70%, which is near median its 10-year median of 18.70 and 142.9% above the Medical Devices & Instruments industry median of 7.70. Svas Biosana SpA's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Svas Biosana SpA (MIL:SVS), the current 3-Year EBITDA Growth Rate is 18.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Svas Biosana SpA (MIL:SVS) Overvalued in 2026?
Based on GuruFocus' analysis, Svas Biosana SpA stock appears to be undervalued.
The current stock price of €8.00 is trading 16.9% below its estimated GF Value™ of €9.63.
GuruFocus considers Svas Biosana SpA to be Modestly Undervalued.
Key valuation signals for MIL:SVS:
3-Year EBITDA Growth Rate: 18.70% (near median its 10-year median of 18.70)
GF Value™: €9.63 vs. price of €8.00 (16.9% below fair value)
Industry Position: 142.9% above the Medical Devices & Instruments median (#246 of 689)
No single metric tells the full story. See the MIL:SVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:SVS has been successfully added to your 
